Back to top
more

Calithera Biosciences (CALA)

(Delayed Data from OTC)

$0.03 USD

0.03
1,075

-0.01 (-37.25%)

Updated Apr 18, 2024 02:55 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

KalVista (KALV) Stock Continues to Decline: Here's Why

by Zacks Equity Research

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug

by Zacks Equity Research

The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.

Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal

by Zacks Equity Research

Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.

Do Options Traders Know Something About Calithera Biosciences (CALA) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates

by Zacks Equity Research

The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.

Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails

by Zacks Equity Research

Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.

Do Options Traders Know Something About Calithera (CALA) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.

Tilray (TLRY) Catches Eye: Stock Jumps 6.3%

by Zacks Equity Research

Tilray (TLRY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (CALA) Outperforming Other Medical Stocks This Year?

Is Calithera Biosciences (CALA) Stock a Solid Choice Right Now?

by Zacks Equity Research

Calithera Biosciences (CALA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

What Makes Calithera (CALA) a New Buy Stock

by Zacks Equity Research

Calithera (CALA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Calithera (CALA) Soars: Stock Adds 9.4% in Session

by Zacks Equity Research

Calithera (CALA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study

by Zacks Equity Research

Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.

Calithera Biosciences Enters Oversold Territory

by Zacks Equity Research

Calithera Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Implied Volatility Surging for Calithera (CALA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.

Analysts Estimate Calithera (CALA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Calithera (CALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Calithera (CALA) Initiates Phase I/II Study of Telaglenastat

by Zacks Equity Research

Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.

Calithera (CALA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Calithera (CALA) delivered earnings and revenue surprises of -26.83% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Calithera (CALA) Q3 Earnings Preview: What to Watch Ahead of the Release

by Zacks Equity Research

Calithera (CALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Calithera (CALA) delivered earnings and revenue surprises of 72.73% and 230.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Calithera's Kidney Cancer Candidate Gets Fast Track Status

    by Zacks Equity Research

    Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.

      Why Calithera Biosciences (CALA) Might Surprise This Earnings Season

      by Zacks Equity Research

      Calithera Biosciences (CALA) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

        The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics